<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>海滨制药 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/haibinzhiyao/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Fri, 16 Apr 2021 02:46:05 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>海滨制药 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国美罗培南单抗市场研究报告</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguomeiluopeinandankangshichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Wed, 14 Apr 2021 02:54:11 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Sumitomo Dainippon Pharma]]></category>
		<category><![CDATA[倍能]]></category>
		<category><![CDATA[安吉利]]></category>
		<category><![CDATA[抗生素]]></category>
		<category><![CDATA[日本住友制药]]></category>
		<category><![CDATA[欧意药业]]></category>
		<category><![CDATA[海口市制药厂]]></category>
		<category><![CDATA[海正美特]]></category>
		<category><![CDATA[海滨制药]]></category>
		<category><![CDATA[瀚晖制药]]></category>
		<category><![CDATA[美平]]></category>
		<category><![CDATA[美罗培南]]></category>
		<category><![CDATA[舒罗克]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=23664</guid>

					<description><![CDATA[CRI元哲的调研数据显示，2016-2019年，美罗培南在中国市场的销售额呈上升趋势。2020年的销售额约为18.8亿元，相较于2019年减少了12.2%。主要原因是2020年初爆发的COVID-19疫情使中国医院整体诊疗业务受到冲击。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
